Our study revealed that T-96 exhibited therapeutic efficacy in our mouse model of vitiligo and had immunosuppressive and migration-blocking effects on CD8+ T cells comparable to the pan-JAK inhibitor Tofa (Fig. 7). Here, CD8A is linked to vitiligo.